Ocular drug delivery – new strategies for targeting anterior and posterior segments of the eye

Current Pharmaceutical Design

Volumn 22, Issue 9, 2016, Pages 1135-1146

  Fangueiro, Joana F ^a,b   Veiga, Francisco ^a,c   Silva, Amélia M ^b,d   Souto, Eliana B ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Colloidal systems; Nanomedicines; Nanoparticles; Nanotechnology; Ocular drug delivery; Ocular therapy

Indexed keywords

CYCLODEXTRIN; DENDRIMER; LIPID; LIPOSOME; NANOCRYSTAL; NANOPARTICLE; POLYMER; PRODRUG; DRUG; EYE DROPS;

COLLOID; DRUG DELIVERY SYSTEM; EYE DISEASE; GENE THERAPY; HUMAN; HYDROPHILICITY; INTRAOCULAR DRUG ADMINISTRATION; MICROEMULSION; MICRONEEDLE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANATOMY AND HISTOLOGY; ANIMAL; EYE; EYE DISEASES;

ADMINISTRATION, OPHTHALMIC; ANIMALS; DRUG DELIVERY SYSTEMS; EYE; EYE DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS;

EID: 84959502618     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151216145900     Document Type: Review

References (164)

1. Araujo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009; 5: 394-401.
2. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res 2010; 27: 530-43.
3. Sharma R, Yassin AE. Nanostructure-based platforms-current prospective in ophthalmic drug delivery. Indian J Ophthalmol 2014; 62(7): 768-72.
4. Rawas-Qalaji M, Williams CA. Advances in ocular drug delivery. Curr Eye Res 2012; 37: 345-56.
5. Sultana Y, Maurya DP, Iqbal Z, Aqil M. Nanotechnology in ocular delivery: current and future directions. Drugs Today (Barc) 2011; 47: 441-55.
6. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des 2009; 15: 2724-50.
7. Xu Q, Kambhampati SP, Kannan RM. Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol 2013; 20: 26-37.
8. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12: 348-60.
9. Gipson IK, Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. Int Rev Cytol 2003; 231: 1-49.
10. Barar J, Asadi M, Mortazavi-Tabatabaei SA, Omidi Y. Ocular drug delivery; impact of in vitro cell culture models. J Ophthalmic Vis Res 2009; 4: 238-52.
11. Torricelli AA, Singh V, Santhiago MR, Wilson SE. The corneal epithelial basement membrane: structure, function, and disease. Invest Ophthalmol Vis Sci 2013; 54: 6390-400.
12. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert Opin Drug Deliv 2008; 5: 567-81.
13. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006; 58: 1131-5.
14. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006; 3: 275-87.
15. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 1998; 87: 1479-88.
16. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discov Today 2011; 16: 270-7.
17. del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: A shift to the posterior segment. Drug Discov Today 2008; 13: 135-43.
18. Hosseini K, Matsushima D, Johnson J, et al. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J Ocul Pharmacol Ther 2008; 24: 301-8.
19. Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 2013; 27: 787-94.
20. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci 2010; 51: 5403-20.
21. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013; 36: 172-98.
22. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008; 13: 144-51.
23. Januleviciene I, Siaudvytyte L, Barsauskaite R. Ophthalmic drug delivery in glaucoma-a review. Pharmaceutics 2012; 4: 243-51.
24. Souto EB, Doktorovova S, Gonzalez-Mira E, Egea MA, Garcia ML. Feasibility of lipid nanoparticles for ocular delivery of antiinflammatory drugs. Curr Eye Res 2010; 35: 537-52.
25. Fangueiro JF, Andreani T, Egea MA, et al. Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int J Pharm 2014; 461: 64-73.
26. Webster TJ. Nanomedicine: what's in a definition? Int J Nanomedicine 2006; 1: 115-6.
27. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005; 57: 1595-1639.
28. Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Souto EB. Experimental factorial design applied to mucoadhesive lipid nanoparticles via multiple emulsion process. Colloids Surf B Biointerfaces 2012; 100: 84-9.
29. Hagerstrom H, Edsman K, Stromme M. Low-frequency dielectric spectroscopy as a tool for studying the compatibility between pharmaceutical gels and mucous tissue. J Pharm Sci 2003; 92: 1869-81.
30. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci 2011; 3: 89-100.
31. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res 2010; 1: 381-7.
32. Andreani T, Miziara L, Lorenzon EN, et al. Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models. Eur J Pharm Biopharm 2015; 93: 118-26.
33. Bhagav P, Trivedi V, Shah D, Chandran S. Sustained release ocular inserts of brimonidine tartrate for better treatment in open-angle glaucoma. Drug Deliv Transl Res 2011; 1: 161-74.
34. Kesavan K, Kant S, Singh PN, Pandit JK. Mucoadhesive chitosancoated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation. Curr Eye Res 2013; 38: 342-52.
35. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403: 185-91.
36. Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm 2010; 36: 108-18.
37. Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Dev Technol 2011; 16: 44-56.
38. Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 2012; 47: 678-85.
39. Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan coated PLA nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in rabbit eye. J Biomed Nanotechnol 2010; 6: 648-57.
40. Calvo P, Vila-Jato JL, Alonso Ma J. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm 1997; 153: 41-50.
41. De Campos AM, Sánchez A, Gref R, Calvo P, Alonso M, AMP, X A J. The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003; 20: 73-81.
42. Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A, Loftsson T. Cyclodextrin-based nanogels for pharmaceutical and biomedical applications. Int J Pharm 2012; 428: 152-63.
43. Zha L, Banik B, Alexis F. Stimulus responsive nanogels for drug delivery. Soft Matter 2011; 7: 5908-16.
44. Samah NA, Williams N, Heard CM. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int J Pharm 2010; 401: 72-8.
45. Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec 2010; 10: 366-76.
46. Sultana Y, Aqil M, Ali A, Zafar S. Evaluation of carbopol-methyl cellulose based sustained-release ocular delivery system for pefloxacin mesylate using rabbit eye model. Pharm Dev Technol 2006; 11: 313-9.
47. Wu C, Qi H, Chen W, et al. Preparation and evaluation of a Carbopol/ HPMC-based in situ gelling ophthalmic system for puerarin. Yakugaku Zasshi 2007; 127: 183-91.
48. Kesavan K, Kant S, Singh PN, Pandit JK. Effect of hydroxypropylbeta-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel. Curr Eye Res 2011; 36: 918-29.
49. Hosny KM. Ciprofloxacin as ocular liposomal hydrogel. AAPS PharmSciTech 2010; 11: 241-6.
50. Budai L, Hajdú M, Budai M, et al. Gels and liposomes in optimized ocular drug delivery: Studies on ciprofloxacin formulations. Int J Pharm 2007; 343: 34-40.
51. Gulsen D, Chauhan A. Dispersion of microemulsion drops in HEMA hydrogel: a potential ophthalmic drug delivery vehicle. Int J Pharm 2005; 292: 95-117.
52. Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and safety. Int J Nanomed 2014; 9: 1025-37.
53. Ye T, Yuan K, Zhang W, et al. Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery. Asian J Pharm Sci 2013; 8: 207-17.
54. Meyer L, Bednarz J, Muller-Goymann CC, Reichl S. Esterase activity of human organotypic cornea construct (HCC) as in vitro model for permeation studies. Ophthalmologe 2005; 102: 971-80.
55. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95: 1177-95.
56. Rautio J, Ed. Prodrug Strategies in Drug Design. In: Prodrugs and Targeted Delivery. Germany: Wiley-VCH Verlag GmbH & Co. KGaA 2010; pp. 1-30.
57. Kwatra D, Vaishya R, Gaudana R, Jwala J, Mitra AK. Ocular Delivery Using Prodrugs. In: Rautio J, Ed. Prodrugs and Targeted Delivery. Germany: Wiley-VCH Verlag GmbH & Co. KGaA 2010; pp. 181-205.
58. Macha S, Duvvuri S, Mitra AK. Ocular disposition of novel lipophilic diester prodrugs of ganciclovir following intravitreal administration using microdialysis. Curr Eye Res 2004; 28: 77-84.
59. Russo A, Riva I, Pizzolante T, Noto F, Quaranta L. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol 2008; 2: 897-905.
60. Järvinen T, Niemi R. Prodrug approaches to ophthalmic drug delivery. In: Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J, Eds. Prodrugs. New York: Springer 2007; pp. 125-55.
61. Chien D-S, Schoenwald R. Ocular pharmacokinetics and pharmacodynamics of phenylephrine and phenylephrine oxazolidine in rabbit eyes. Pharm Res 1990; 7: 476-83.
62. Cynkowska G, Cynkowski T, Al-Ghananeem AM, Guo H, Ashton P, Crooks PA. Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg Med Chem Lett 2005; 15: 3524-7.
63. Rao JP, Geckeler KE. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog Polymer Sci 2011; 36: 887-913.
64. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm 2010; 385: 113-42.
65. de Campos AM, Diebold Y, Carvalho EL, Sanchez A, Alonso MJ. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004; 21: 803-10.
66. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target 2010; 18: 292-302.
67. Gan L, Wang J, Zhao Y, et al. Hyaluronan-modified core-shell liponanoparticles targeting CD44-positive retinal pigment epithelium cells via intravitreal injection. Biomaterials 2013; 34: 5978-87.
68. Costa JR, Silva NC, Sarmento B, Pintado M. Potential chitosancoated alginate nanoparticles for ocular delivery of daptomycin. Eur J Clin Microbiol Infect Dis 2015; 34: 1255-62.
69. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008; 68: 513-25.
70. Enriquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006; 47: 1416-25.
71. Contreras-Ruiz L, de la Fuente M, Garcia-Vazquez C, et al. Ocular tolerance to a topical formulation of hyaluronic acid and chitosanbased nanoparticles. Cornea 2010; 29: 550-8.
72. Contreras-Ruiz L, de la Fuente M, Parraga JE, et al. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol Vis 2011; 17: 279-90.
73. Hsu SH, Ho TT, Tseng TC. Nanoparticle uptake and gene transfer efficiency for MSCs on chitosan and chitosan-hyaluronan substrates. Biomaterials 2012; 33: 3639-50.
74. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Control Release 2009; 136: 2-13.
75. Hegde RR, Verma A, Ghosh A. Microemulsion: new insights into the ocular drug delivery. ISRN Pharm 2013; 2013: 826798.
76. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res 2002; 21: 15-34.
77. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retinal Eye Res 2002; 21: 15-34.
78. Chan J, Maghraby GMME, Craig JP, Alany RG. Phase transition water-in-oil microemulsions as ocular drug delivery systems: In vitro and in vivo evaluation. Int J Pharm 2007; 328: 65-71.
79. Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention. J Control Release 2006; 111: 145-52.
80. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-IN27.
81. Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv 2011; 2011: 14.
82. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013; 65: 36-48.
83. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 2009; 379: 131-8.
84. Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposome–chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007; 28: 1553-64.
85. de Sa FA, Taveira SF, Gelfuso GM, Lima EM, Gratieri T. Liposomal voriconazole (VOR) formulation for improved ocular delivery. Colloids Surf B Biointerfaces 2015; 133: 331-8.
86. Vicario-de-la-Torre M, Benitez-del-Castillo JM, Vico E, et al. Design and characterization of an ocular topical liposomal preparation to replenish the lipids of the tear film. Invest Ophthalmol Vis Sci 2014; 55: 7839-47.
87. Souto E, Fangueiro J, Müller R. Solid Lipid Nanoparticles (SLN™). In: Uchegbu IF, Schätzlein AG, Cheng WP, Lalatsa A, Eds. Fundamentals of Pharmaceutical Nanoscience. New York: Springer 2013; pp. 91-116.
88. Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 2010; 17: 467-89.
89. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2013; 453: 167-80.
90. Tiwari G, Tiwari R, Rai AK. Cyclodextrins in delivery systems: Applications. J Pharm Bioallied Sci 2010; 2: 72-9.
91. Oda M, Saitoh H, Kobayashi M, Aungst BJ. β-Cyclodextrin as a suitable solubilizing agent for in situ absorption study of poorly water-soluble drugs. Int J Pharm 2004; 280: 95-102.
92. Loftsson T, Stefansson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 2002; 80: 144-50.
93. Kaur IP, Chhabra S, Aggarwal D. Role of cyclodextrins in ophthalmics. Curr Drug Deliv 2004; 1: 351-60.
94. He ZX, Wang ZH, Zhang HH, et al. Doxycycline and hydroxypropyl-β-cyclodextrin complex in poloxamer thermal sensitive hydrogel for ophthalmic delivery. Acta Pharm Sin B 2011; 1: 254-60.
95. Fernandez-Ferreiro A, Fernandez Bargiela N, Varela MS, et al. Cyclodextrin-polysaccharide-based, in situ-gelled system for ocular antifungal delivery. Beilstein J Org Chem 2014; 10: 2903-11.
96. Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed 2008; 3: 295-309.
97. Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci 2015; 10: 13-23.
98. Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm 2014; 467: 34-41.
99. Tomalia DA, Baker H, Dewald J, et al. A new class of polymers: starburst-dendritic macromolecules. Polym J 1985; 17: 117-32.
100. Vandervoort J, Ludwig A. Ocular drug delivery: nanomedicine applications. Nanomedicine (Lond) 2007; 2: 11-21.
101. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 2014; 6: 139-50.
102. Samad A, Alam MI, Saxena K. Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals. Curr Pharm Des 2009; 15: 2958-69.
103. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005; 23: 1517-26.
104. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005; 12: 1544-50.
105. Nishiyama N, Iriyama A, Jang WD, et al. Light-induced gene transfer from packaged DNA enveloped in a dendrimeric photosensitizer. Nat Mater 2005; 4: 934-41.
106. Khandan O, Famili A, Kahook MY, Rao MP. Titanium-based, fenestrated, in-plane microneedles for passive ocular drug delivery. Conf Proc IEEE Eng Med Biol Soc 2012; 2012: 6572-5.
107. Kim YC, Oh KH, Edelhauser HF, Prausnitz MR. Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles. Eur J Pharm Biopharm 2015; 95(Pt B): 398-406.
108. Jiang J, Moore JS, Edelhauser HF, Prausnitz MR. Intrascleral drug delivery to the eye using hollow microneedles. Pharm Res 2009; 26: 395-403.
109. Patel SR, Lin AS, Edelhauser HF, Prausnitz MR. Suprachoroidal drug delivery to the back of the eye using hollow microneedles. Pharm Res 2011; 28: 166-76.
110. Jiang J, Gill HS, Ghate D, et al. Coated microneedles for drug delivery to the eye. Invest Ophthalmol Vis Sci 2007; 48: 4038-43.
111. Gonzalez-Mira E, Egea MA, Souto EB, Calpena AC, Garcia ML. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011; 22: 045101.
112. Abrego G, Alvarado HL, Egea MA, Gonzalez-Mira E, Calpena AC, Garcia ML. Design of nanosuspensions and freeze-dried PLGA nanoparticles as a novel approach for ophthalmic delivery of pranoprofen. J Pharm Sci 2014; 103: 3153-64.
113. Adibkia K, Siahi Shadbad MR, Nokhodchi A, et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 2007; 15: 407-16.
114. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008; 355: 307-13.
115. Jafariazar Z, Jamalinia N, Ghorbani-Bidkorbeh F, Mortazavi SA. Design and Evaluation of Ocular Controlled Delivery System for Diclofenac Sodium. Iran J Pharm Res 2015; 14: 23-31.
116. Yu S, Wang Q-M, Wang X, et al. Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate. Int J Pharm 2015; 480: 128-36.
117. Agnihotri SA, Aminabhavi TM. Chitosan nanoparticles for prolonged delivery of timolol maleate. Drug Dev Ind Pharm 2007; 33: 1254-62.
118. Lutfi G, Muzeyyen D. Preparation and characterization of polymeric and lipid nanoparticles of pilocarpine HCl for ocular application. Pharm Dev Technol 2013; 18: 701-9.
119. Li J, Guo X, Liu Z, et al. Preparation and evaluation of charged solid lipid nanoparticles of tetrandrine for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. Drug Dev Ind Pharm 2014; 40: 980-7.
120. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech 2007; 8: 1.
121. Singh J, Chhabra G, Pathak K. Development of acetazolamideloaded, pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery: in vitro. ex vivo evaluation and pharmacodynamic study. Drug Dev Ind Pharm 2014; 40: 1223-32.
122. Ustundag-Okur N, Gokce EH, Egrilmez S, Ozer O, Ertan G. Novel ofloxacin-loaded microemulsion formulations for ocular delivery. J Ocul Pharmacol Ther 2014; 30: 319-32.
123. Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine 2010; 6: 324-33.
124. Gadad AP, Chandra PS, Dandagi PM, Mastiholimath VS. Moxifloxacin loaded polymeric nanoparticles for sustained ocular drug delivery. Int J Pharm Sci Nanotechnol 2012; 5: 1727-34.
125. Kumar R, Sinha VR. Preparation and optimization of voriconazole microemulsion for ocular delivery. Colloids Surf B Biointerfaces 2014; 117: 82-8.
126. Mohammed N, Rejinold NS, Mangalathillam S, Biswas R, Nair SV, Jayakumar R. Fluconazole loaded chitin nanogels as a topical ocular drug delivery agent for corneal fungal infections. J Biomed Nanotechnol 2013; 9: 1521-31.
127. Gratieri T, Gelfuso GM, de Freitas O, Rocha EM, Lopez RF. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur J Pharm Biopharm 2011; 79: 320-7.
128. Hosny KM. Optimization of gatifloxacin liposomal hydrogel for enhanced transcorneal permeation. J Liposome Res 2010; 20: 31-7.
129. Wagh VD, Apar DU. Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies. J Nanotechnol 2014; 2014: 10.
130. Basaran E, Yenilmez E, Berkman MS, Buyukkoroglu G, Yazan Y. Chitosan nanoparticles for ocular delivery of cyclosporine A. J Microencapsul 2014; 31: 49-57.
131. Basaran E, Demirel M, Sirmagul B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nanoparticles for ocular delivery. J Microencapsul 2010; 27: 37-47.
132. Varia JK, Dodiya SS, Sawant KK. Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Curr Drug Deliv 2008; 5: 64-9.
133. Gross N, Ranjbar M, Evers C, et al. Choroidal neovascularization reduced by targeted drug delivery with cationic liposomeencapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol Vis 2013; 19: 54-61.
134. Fangueiro JF, Andreani T, Fernandes L, et al. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf B Biointerfaces 2014; 123: 452-60.
135. Araujo J, Nikolic S, Egea MA, Souto EB, Garcia ML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces 2011; 88: 150-7.
136. Lu Y, Zhou N, Huang X, et al. Effect of intravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophthalmol 2014; 7: 1-7.
137. Patel SR, Berezovsky DE, McCarey BE, Zarnitsyn V, Edelhauser HF, Prausnitz MR. Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2012; 53: 4433-41.
138. Song HB, Lee KJ, Seo IH, et al. Impact insertion of transfermolded microneedle for localized and minimally invasive ocular drug delivery. J Control Release 2015; 209: 272-279.
139. Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes. AAPS J 2007; 9: E371-7.
140. Akhter S, Ramazani F, Ahmad MZ, et al. Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovirloaded mucoadhesive nanoparticles in rabbits. Eur J Nanomed 2013; 5: 159-67.
141. Liu MM, Tuo J, Chan CC. Republished review: Gene therapy for ocular diseases. Postgrad Med J 2011; 87: 487-95.
142. Solinís MÁ, del Pozo-Rodríguez A, Apaolaza PS, Rodríguez-Gascón A. Treatment of ocular disorders by gene therapy. Eur J Pharm Biopharm 2015; 95(Pt B): 331-42.
143. Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res 2008; 48: 319-24.
144. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014; 15: 541-55.
145. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retinal Eye Res 2010; 29: 376-97.
146. Zorzi GK, Parraga JE, Seijo B, Sanchez A. Comparison of different cationized proteins as biomaterials for nanoparticle-based ocular gene delivery. Colloids Surf B Biointerfaces 2015; 135: 533-41.
147. Zorzi GK, Parraga JE, Seijo B, Sanchez A. Hybrid nanoparticle design based on cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene therapy. Macromol Biosci 2011; 11: 905-13.
148. Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles. J Pharm Sci 2005; 94: 184-98.
149. Sun D, Maeno H, Gujrati M, et al. Self-Assembly of a multifunctional lipid with core-shell dendrimer DNA nanoparticles enhanced efficient gene delivery at low charge ratios into RPE cells. Macromol Biosci 2015; [Epub ahead of print].
150. Gerometta R, Spiga MG, Borras T, Candia OA. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoidinducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci 2010; 51: 3042-8.
151. Chen Y, Moiseyev G, Takahashi Y, Ma JX. RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65-/-mice. Invest Ophthalmol Vis Sci 2006; 47: 1177-84.
152. Campochiaro PA. Gene transfer for neovascular age-related macular degeneration. Hum Gene Ther 2011; 22: 523-9.
153. Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One 2011; 6: e19078.
154. Lamartina S, Cimino M, Roscilli G, et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J Gene Med 2007; 9: 862-74.
155. Parker DG, Kaufmann C, Brereton HM, et al. Lentivirus-mediated gene transfer to the rat, ovine and human cornea. Gene Ther 2007; 14: 760-7.
156. Parker DG, Coster DJ, Brereton HM, et al. Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Exp Ophthalmol 2010; 38: 405-13.
157. Blalock EL, Chien H, Dix RD. Murine cytomegalovirus downregulates interleukin-17 in mice with retrovirus-induced immunosuppression that are susceptible to experimental cytomegalovirus retinitis. Cytokine 2013; 61: 862-875.
158. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029-32.
159. Jooss K, Chirmule N. Immunity to adenovirus and adenoassociated viral vectors: implications for gene therapy. Gene Ther 2003; 10: 955-63.
160. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11 Suppl 1: S10-7.
161. Provost N, Le Meur G, Weber M, et al. Biodistribution of rAAV vectors following intraocular administration: Evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol Ther 2005; 11: 275-83.
162. Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Non-viral ocular gene therapy: Potential ocular therapeutic avenues. Adv Drug Deliv Rev 2006; 58: 1224-42.
163. Pignatello R, Puglisi G. Nanotechnology in ophthalmic drug delivery: A survey of recent developments and patenting activity. Rec Pat Nanomed 2011; 1: 42-54.
164. Murthy RR. Challenges and Emerging Issues in Patenting Nanomedicines. In: Souto EB, Ed. Patenting Nanomedicines. Berlin Heidelberg: Springer 2012; pp. 25-48.